INDV
Indivior Pharmaceuticals Inc
Drug Manufacturers - Specialty & Generic
Market Cap$4.94B
5Y Perf.+890.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
INDV vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
CVS
CVS Health Corporation
Medical - Healthcare Plans
Market Cap$111.40B
5Y Perf.+33.2%
INDV vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | INDV | CVS |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Healthcare Plans |
| Market Cap | $4.94B | $111.40B |
| Revenue (TTM) | $1.29B | $407.90B |
| Net Income (TTM) | $251M | $2.93B |
| Gross Margin | 83.1% | 13.9% |
| Operating Margin | 33.3% | 1.5% |
| Forward P/E | 12.7x | 12.2x |
| Total Debt | $351M | $93.59B |
| Cash & Equiv. | $195M | $8.51B |
INDV vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INDV
CVS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Indivior Pharmaceut… (INDV) | 100 | 990.0 | +890.0% |
| CVS Health Corporat… (CVS) | 100 | 133.2 | +33.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INDV vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CVS leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Indivior Pharmaceuticals Inc is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
INDV
Indivior Pharmaceuticals Inc
The Income Pick
INDV is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.68
- Rev growth 4.3%, EPS growth 108.3%, 3Y rev CAGR 11.2%
- 281.7% 10Y total return vs CVS's 3.5%
Best for: income & stability and growth exposure
CVS
CVS Health Corporation
The Insurance Pick
CVS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.05, current ratio 0.84x
- Beta 0.05, yield 3.1%, current ratio 0.84x
- 7.8% revenue growth vs INDV's 4.3%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CVS | 7.8% revenue growth vs INDV's 4.3% |
| Value | CVS | Lower P/E (12.2x vs 12.7x) |
| Quality / Margins | INDV | 19.4% margin vs CVS's 0.7% |
| Stability / Safety | CVS | Beta 0.05 vs INDV's 0.68 |
| Dividends | CVS | 3.1% yield; the other pay no meaningful dividend |
| Momentum (1Y) | INDV | +244.9% vs CVS's +34.7% |
| Efficiency (ROA) | INDV | 19.1% ROA vs CVS's 1.1%, ROIC 342.7% vs 5.0% |
INDV vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
INDV vs CVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINDVLAGGINGCVS
CVSCVS Health Corporation
2leads
INDVIndivior Pharmaceutic…
4leads
6 Total Categories
CATEGORYLEADERvs CVSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INDV5/6
Valuation MetricsMultiples, price ratios, and targets
CVS3/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
INDV6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
INDV6/6
Risk & VolatilityBeta, volatility, and downside exposure
CVS2/2
Analyst OutlookRatings, price targets, and dividends
INDV1/1
Income & Cash Flow (Last 12 Months)
INDV leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS is the larger business by revenue, generating $407.9B annually — 316.0x INDV's $1.3B. INDV is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to CVS's 0.7%. On growth, INDV holds the edge at +19.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | INDVIndivior Pharmace… | CVSCVS Health Corpor… |
|---|---|---|
| RevenueTrailing 12 months | $1.3B | $407.9B |
| EBITDAEarnings before interest/tax | $447M | $10.5B |
| Net IncomeAfter-tax profit | $251M | $2.9B |
| Free Cash FlowCash after capex | -$185M | $7.4B |
| Gross MarginGross profit ÷ Revenue | +83.1% | +13.9% |
| Operating MarginEBIT ÷ Revenue | +33.3% | +1.5% |
| Net MarginNet income ÷ Revenue | +19.4% | +0.7% |
| FCF MarginFCF ÷ Revenue | -14.3% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.2% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +81.6% | +63.1% |
INDV leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
CVS leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
At 24.1x trailing earnings, INDV trades at a 62% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than INDV's 17.9x.
| Metric | INDVIndivior Pharmace… | CVSCVS Health Corpor… |
|---|---|---|
| Market CapShares × price | $4.9B | $111.4B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $196.5B |
| Trailing P/EPrice ÷ TTM EPS | 24.15x | 62.81x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.65x | 12.19x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.88x | 13.11x |
| Price / SalesMarket cap ÷ Revenue | 3.99x | 0.28x |
| Price / BookPrice ÷ Book value/share | — | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | 14.27x |
CVS leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
INDV leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), CVS scores 5/9 vs INDV's 4/9, reflecting solid financial health.
| Metric | INDVIndivior Pharmace… | CVSCVS Health Corpor… |
|---|---|---|
| ROE (TTM)Return on equity | — | +3.9% |
| ROA (TTM)Return on assets | +19.1% | +1.1% |
| ROICReturn on invested capital | +3.4% | +5.0% |
| ROCEReturn on capital employed | +79.1% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 1.24x |
| Net DebtTotal debt minus cash | $156M | $85.1B |
| Cash & Equiv.Liquid assets | $195M | $8.5B |
| Total DebtShort + long-term debt | $351M | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | 10.88x | 2.11x |
INDV leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
INDV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INDV five years ago would be worth $36,837 today (with dividends reinvested), compared to $11,700 for CVS. Over the past 12 months, INDV leads with a +244.9% total return vs CVS's +34.7%. The 3-year compound annual growth rate (CAGR) favors INDV at 25.4% vs CVS's 11.0% — a key indicator of consistent wealth creation.
| Metric | INDVIndivior Pharmace… | CVSCVS Health Corpor… |
|---|---|---|
| YTD ReturnYear-to-date | +10.8% | +10.6% |
| 1-Year ReturnPast 12 months | +244.9% | +34.7% |
| 3-Year ReturnCumulative with dividends | +97.0% | +36.6% |
| 5-Year ReturnCumulative with dividends | +268.4% | +17.0% |
| 10-Year ReturnCumulative with dividends | +281.7% | +3.5% |
| CAGR (3Y)Annualised 3-year return | +25.4% | +11.0% |
INDV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than INDV's 0.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | INDVIndivior Pharmace… | CVSCVS Health Corpor… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 0.05x |
| 52-Week HighHighest price in past year | $41.00 | $88.63 |
| 52-Week LowLowest price in past year | $10.63 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +96.6% | +98.5% |
| RSI (14)Momentum oscillator 0–100 | 79.6 | 69.3 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 7.4M |
CVS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
INDV leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates INDV as "Buy" and CVS as "Buy". Consensus price targets imply 12.8% upside for INDV (target: $45) vs 9.0% for CVS (target: $95). CVS is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.
| Metric | INDVIndivior Pharmace… | CVSCVS Health Corpor… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $44.67 | $95.20 |
| # AnalystsCovering analysts | 3 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +3.1% |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
INDV leads this category, winning 1 of 1 comparable metric.
Key Takeaway
INDV leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Valuation Metrics, Risk & Volatility).
Best OverallIndivior Pharmaceuticals Inc (INDV)Leads 4 of 6 categories
Loading custom metrics...
INDV vs CVS: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is INDV or CVS a better buy right now?
For growth investors, CVS Health Corporation (CVS) is the stronger pick with 7.
8% revenue growth year-over-year, versus 4. 3% for Indivior Pharmaceuticals Inc (INDV). Indivior Pharmaceuticals Inc (INDV) offers the better valuation at 24. 1x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INDV or CVS?
On trailing P/E, Indivior Pharmaceuticals Inc (INDV) is the cheapest at 24.
1x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — INDV or CVS?
Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +268.
4%, compared to +17. 0% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: INDV returned +281. 7% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INDV or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Indivior Pharmaceuticals Inc's 0. 68β — meaning INDV is approximately 1238% more volatile than CVS relative to the S&P 500.
05Which is growing faster — INDV or CVS?
By revenue growth (latest reported year), CVS Health Corporation (CVS) is pulling ahead at 7.
8% versus 4. 3% for Indivior Pharmaceuticals Inc (INDV). On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108. 3% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, INDV leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INDV or CVS?
Indivior Pharmaceuticals Inc (INDV) is the more profitable company, earning 16.
9% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 16. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INDV leads at 21. 4% versus 2. 6% for CVS. At the gross margin level — before operating expenses — INDV leads at 80. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INDV or CVS more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
2x forward P/E versus 12. 7x for Indivior Pharmaceuticals Inc — 0. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INDV: 12. 8% to $44. 67.
08Which pays a better dividend — INDV or CVS?
In this comparison, CVS (3.
1% yield) pays a dividend. INDV does not pay a meaningful dividend and should not be held primarily for income.
09Is INDV or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, INDV: +281. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INDV and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INDV is a small-cap quality compounder stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while INDV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(INDV: 19.2% · CVS: 6.2%)P/E Ratio<
x
(INDV: 24.1x · CVS: 62.8x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.